Zhi Tong Cai Jing·2025-08-29 09:31Core Viewpoint - Company subsidiary Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. has received the approval notice for the listing application of structured triglycerides from the National Medical Products Administration, indicating compliance with national drug review technical standards and enabling production and sales [1] Group 1: Product Approval - The approval pertains to structured triglycerides, which are key raw materials for formulations such as structured fat emulsion injection (C6–24) and structured fat emulsion (20%)/ amino acids (16)/ glucose (13%) injection [1] - Structured triglycerides are suitable for patients who cannot, insufficiently, or are contraindicated from oral or enteral nutrition, providing parenteral nutrition fat supplementation [1] Group 2: Market Impact - The approval will enrich the company's medicinal lipid raw material product offerings and enhance the market competitiveness of Baiyunshan Hanfang's lipid raw material products [1] - The approval is not expected to have a significant impact on the company's current performance [1]